Feature | April 08, 2014

GE Healthcare Receives FDA for Q.Clear PET/CT Technology

Technology can enable clinicians to assess patient's response to treatment accurately

GE Healthcare Q.Clear Technology PET/CT Systems Nuclear Imaging

April 8, 2014 — GE Healthcare received U.S. Food and Drug Administration (FDA) 510(k) clearance of its Q.Clear technology, which is designed to provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging. 

Over the last decade, positron emission tomography (PET) image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as time of flight (TOF) and OSEM, force a compromise between image quality and quantitation. GE Healthcare said its Q.Clear technology brings convergence to PET imaging without the need for compromise between quantitation and image quality.

"Q.Clear is a major step forward because it can give us a consistent and reliable measurement when determining whether the current course of a patient's cancer treatment is effective," said Dr. Gustav von Schulthess, nuclear medicine chair at University Hospital Zurich. "It will give the oncologist more confidence because if a change of therapy is needed, you want accurate information early on to best adjust treatment for the patient."

Clinicians not only want the ability to detect smaller lesions, but the ability to determine earlier whether the patient is responding to current treatment. Q.Clear aims to help in both areas by providing better quantitation accuracy for truly personalized medicine. Coupled with Q.Suite, which introduced the importance of eliminating variability such as respiratory motion, Q.Clear can enable clinicians to assess treatment response accurately.

"We know that approximately 70 percent of cancer patients don't always respond to their initial course of treatment," said Steve Gray, president and CEO of GE Healthcare MICT. "If we can give clinicians an accurate, reliable, and faster tool to confirm that a change in treatment is needed, the patient will benefit greatly. For example, PET/computed tomography (CT) can help clinicians determine whether chemotherapy is working in fewer cycles, saving patients unnecessary procedures.  Q.Clear gives clinicians the ability to help make that determination."

GE said the system may not be available for sale in all regions. For countries that require CE marking, Q.Clear is not yet CE marked.

For more information: www3.gehealthcare.com

Related Content

The interior of the German air force Airbus A-310 Medivac in Cologne, Germany, before its departure to Bergamo, Italy, March 28 to being ferrying COVID-19 patients to Germany for treatment to aid the Italians, whose healthcare system has been overwhelmed by the rapid spread of the coronavirus pandemic. Bundeswehr Photo by Kevin Schrief.

The interior of the German air force Airbus A-310 Medivac in Cologne, Germany, before its departure to Bergamo, Italy, March 28 to being ferrying COVID-19 patients to Germany for treatment to aid the Italians, whose healthcare system has been overwhelmed by the rapid spread of the coronavirus pandemic. Bundeswehr Photo by Kevin Schrief. Find more images from the COVID-19 pandemic.

 

Feature | Coronavirus (COVID-19) | April 08, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
A University of Colorado Cancer Center study published in the Journal of the National Cancer Institute shows an important predictor of PET-CT use

Rustain Morgan, M.D., and colleagues show racial/ethnic disparities in use of important imaging during lung cancer diagnosis. Photo courtesy of University of Colorado Cancer Center

News | PET-CT | March 12, 2020
March 12, 2020 — The use of PET-CT
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
MR Solutions’ dry magnet MRI system for molecular imaging on display at EMIM 2020
News | Magnetic Resonance Imaging (MRI) | February 28, 2020
February 28, 2020 — MR Solutions will be displaying its la